{"schema_version":"secwatch.filing_event.v1","accession":"0001001233-26-000005","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2026-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.366942+00:00","generated_at":"2026-05-16T05:12:54.258604+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sangamo: ST-920 Phase 1/2 data positive; FDA agrees to Accelerated Approval path","bullets":["FDA agreed Phase 1/2 STAAR data can support Accelerated Approval using eGFR slope at 52 weeks; rolling BLA started Dec 2025.","Positive mean annualized eGFR slope of 1.965 at Week 52 (95% CI -0.153, 4.083) across 32 patients; Week 104 slope 1.747.","All 15 ERT-naïve patients achieved normal/supraphysiological α-Gal A activity up to 54 months; 18 ERT patients safely withdrew from ERT.","32 of 33 patients completed 52-week follow-up; ST-920 well-tolerated with no discontinuations due to AEs, no TMA or complement activation.","Statistically significant improvements in SF-36 QoL and GSRS diarrhea scores at Week 52; anti-α-Gal A antibodies reduced/eliminated in 9/10 patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001001233-26-000005","json":"https://secwatch.observer/filing/0001001233-26-000005.json","markdown":"https://secwatch.observer/filing/0001001233-26-000005.md","text":"https://secwatch.observer/filing/0001001233-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000100123326000005/0001001233-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000100123326000005/sgmo-20260203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:12:54.258604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}